We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AZO:NYSEAutoZone, Inc. Analysis

Data as of 2026-03-10 - not real-time

$3,672.68

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

AutoZone (AZO) trades at $3,672.68, just below its 20‑day SMA of 3,732.81 and under the 200‑day SMA of 3,809.65, indicating a short‑term pullback within a neutral longer‑term trend. The RSI of 48.3 suggests neither overbought nor oversold conditions, while the MACD histogram is negative (-16.25), reinforcing a bearish momentum bias. Despite a 30‑day volatility of 34.6%, the stock’s beta is low at 0.18, implying limited sensitivity to broader market swings. Fundamentals show solid top‑line health with 8.2% revenue growth and healthy margins (gross 51.9%, operating 16.3%), yet cash generation is weak and debt sits at $12.5 B against only $0.29 B of cash, resulting in a negative book value per share. Analyst consensus remains a “Buy” with a median price target of $4,300, implying about a 15% upside and the market sentiment is in “Extreme Greed” (Fear‑Greed Index 75.9). Recent Q2 earnings delivered strong sales (+8.1%) but missed earnings expectations, triggering a modest price dip and highlighting margin pressure from LIFO adjustments. Overall, the stock balances growth potential against balance‑sheet constraints, making it a nuanced play for investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and price below short‑term SMA
  • Recent earnings miss and margin pressure
  • Increasing volume but lower than average daily volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of 8% and strong operating margins
  • Analyst price targets indicating ~15% upside
  • Low beta reducing market‑wide volatility exposure

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Market‑leading position in auto parts with durable demand
  • Consistent earnings growth and forward EPS expansion
  • High debt offset by stable cash flows and brand strength

Key Metrics & Analysis

Financial Health

Revenue Growth8.20%
Profit Margin12.47%
P/E Ratio25.7
ROA11.50%
P/B Ratio-20.9

Technical Analysis

TrendNeutral
RSI48.3
Support$3,561.57
Resistance$3,887.03
MA 20$3,732.81
MA 50$3,618.95
MA 200$3,809.65
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Target Price$4,225.38
Upside/Downside15.05%
GradeFair
TypeBlend

Risk Assessment

Beta0.18
Volatility34.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.